Why Is SPYRE THERAPEUTICS I (SYRE) Stock Down Today?

SYRE stock closed down 4.79% at $100.28 after a sharp intraday decline that followed a modest opening gap. The move came despite the company announcing the launch of its SPY772 program and the initiation of a Phase 2 trial for hidradenitis suppurativa. The session saw unusually low volume and a sharp drop from the morning high, suggesting a rapid shift in investor sentiment.

What Happened

Spyre Therapeutics announced the launch of its SPY772 program, which combines two long-acting antibodies targeting inflammatory pathways. This development was intended to signal progress in its pipeline, with the initiation of the Phase 2 SKYLIGHT trial in hidradenitis suppurativa. However, the stock opened at $104.70, down 0.6% from the previous close, and quickly fell to a session low of $99.84. The stock closed at $100.28, down 4.79% from the prior close of $105.33. The decline occurred despite recent analyst activity, including price target increases from BTIG, Wells Fargo, and Guggenheim.

What The Data Shows

The stock traded at a volume of 0.1M shares, which is 0.1x the 3-month daily average, indicating minimal participation. Over the past 8 sessions, the stock had risen 4.4% from $101.50 to $106.00. However, the recent session’s sharp drop reversed much of that gain. Insider transactions over the last 90 days totaled 12 sells worth $412.4M, with recent sales reported from the CEO, CFO, and a director. These exits may have contributed to the downward pressure on the stock.

What To Watch

The stock is set to continue trading with heightened sensitivity to its clinical trial progress and analyst commentary. Investors may look for further coverage or updates from the company regarding the SPY772 program and the SKYLIGHT trial.